A novel immune cell signature for predicting glioblastoma after radiotherapy prognosis and guiding therapy

Conclusion: The immune cell signature, comprising SDC-1, PLAUR, FN1, and CXCL13, holds promise as a predictive tool for assessing glioblastoma prognosis following radiotherapy. This signature also offers valuable guidance for tailoring treatment strategies, emphasizing its potential clinical relevance in improving patient outcomes.PMID:38687369 | DOI:10.1177/03946320241249395
Source: International Journal of Immunopathology and Pharmacology - Category: Allergy & Immunology Authors: Source Type: research